We are live on ! Find out more
SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

7 hedge funds and large institutions have $12.4K invested in Syros Pharmaceuticals, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

84% less funds holding

Funds holding: 44 → 7 (-37)

97% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 38

99% less capital invested

Capital invested by funds: $1.2M → $12.4K (-$1.19M)

Holders
7
Holders Change
-37
Holders Change %
-84.09%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
1
Closed
38
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$13.6K
2
BBA
Baader Bank Aktiengesellschaft
Germany
+$10.4K
3
FIA
FNY Investment Advisers
New York
+$1.85K
4
Simplex Trading
Simplex Trading
Illinois
+$695

Top Sellers

Rank Fund Capital Flow
1
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$632K
2
BlackRock
BlackRock
New York
-$63.7K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$61.7K
4
OFM
Omega Fund Management
Massachusetts
-$57.8K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$45.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
1
Acadian Asset Management
Massachusetts
$9K +$13.6K +80,367 +32%
BBA
2
Baader Bank Aktiengesellschaft
Germany
$1.91K +$10.4K +61,772 +280%
1CM
3
1492 Capital Management
Wisconsin
$1.18K – – –
XT
4
XTX Topco
Cayman Islands
$290 -$12K -71,407 -88%
BCLSI
5
Bain Capital Life Sciences Investors
Massachusetts
– -$632K -2,750,151 Closed
BlackRock
6
BlackRock
New York
– -$63.7K -277,253 Closed
Vanguard Group
7
Vanguard Group
Pennsylvania
– -$61.7K -268,154 Closed
OFM
8
Omega Fund Management
Massachusetts
– -$57.8K -251,270 Closed
Geode Capital Management
9
Geode Capital Management
Massachusetts
– -$45.1K -196,252 Closed
AAA
10
Affinity Asset Advisors
New York
– -$34.5K -150,000 Closed
Citigroup
11
Citigroup
New York
– -$32K -139,224 Closed
Qube Research & Technologies (QRT)
12
Qube Research & Technologies (QRT)
United Kingdom
– -$28.1K -122,174 Closed
TSS
13
Two Sigma Securities
New York
– -$24.8K -107,742 Closed
Renaissance Technologies
14
Renaissance Technologies
New York
– -$22.1K -96,042 Closed
HF
15
HRT Financial
New York
– -$20K -87,535 Closed
State Street
16
State Street
Massachusetts
– -$16K -69,430 Closed
Jane Street
17
Jane Street
New York
– -$12.2K -52,920 Closed
Two Sigma Investments
18
Two Sigma Investments
New York
– -$11.2K -48,861 Closed
UBS Group
19
UBS Group
Switzerland
– -$10.4K -45,050 Closed
Northern Trust
20
Northern Trust
Illinois
– -$9.38K -40,812 Closed
VF
21
Virtu Financial
New York
– -$8K -32,791 Closed
CGL
22
Clarius Group LLC
Washington
– -$4.28K -18,620 Closed
MG
23
Marex Group
– -$3.84K -16,700 Closed
HighTower Advisors
24
HighTower Advisors
Illinois
– -$3.42K -14,898 Closed
Corient Private Wealth
25
Corient Private Wealth
Florida
– -$2.76K -12,000 Closed
1
2

SYRS Hedge Fund Activity: Q1 2025 in Review

7 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2025, worth a combined $12.4K — down 99% from $1.2M a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of SYRS and 1 opened new positions — a net loss of 37 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was Acadian Asset Management, adding an estimated $13.6K. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $632K sold.

  • 7 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2025, down from 44 in Q4 2024.
  • Funds reported $12.4K of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2025, down 99% quarter-over-quarter.
  • 1 fund opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2025 and 38 closed out, a net change of -37 holders.
  • The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2025 was Acadian Asset Management, an estimated $13.6K added.
  • The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2025 was Bain Capital Life Sciences Investors, an estimated $632K sold.

Based on aggregated 13F filings for Q1 2025.